FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885472080> ?p ?o ?g. }

• W2885472080 abstract "Background Subarachnoid haemorrhage has an incidence of up to nine per 100,000 person-years. It carries a mortality of 30% to 45% and leaves 20% dependent in activities of daily living. The major causes of death or disability after the haemorrhage are delayed cerebral ischaemia and rebleeding. Interventions aimed at lowering blood pressure may reduce the risk of rebleeding, while the induction of hypertension may reduce the risk of delayed cerebral ischaemia. Despite the fact that medical alteration of blood pressure has been clinical practice for more than three decades, no previous systematic reviews have assessed the beneficial and harmful effects of altering blood pressure (induced hypertension or lowered blood pressure) in people with acute subarachnoid haemorrhage. Objectives To assess the beneficial and harmful effects of altering arterial blood pressure (induced hypertension or lowered blood pressure) in people with acute subarachnoid haemorrhage. Search methods We searched the following from inception to 8 September 2020 (Chinese databases to 27 January 2019): Cochrane Stroke Group Trials register; CENTRAL; MEDLINE; Embase; five other databases, and five trial registries. We screened reference lists of review articles and relevant randomised clinical trials. Selection criteria Randomised clinical trials assessing the effects of inducing hypertension or lowering blood pressure in people with acute subarachnoid haemorrhage. We included trials irrespective of publication type, status, date, and language. Data collection and analysis Two review authors independently extracted data. We assessed the risk of bias of all included trials to control for the risk of systematic errors. We performed trial sequential analysis to control for the risks of random errors. We also applied GRADE. Our primary outcomes were death from all causes and death or dependency. Our secondary outcomes were serious adverse events, quality of life, rebleeding, delayed cerebral ischaemia, and hydrocephalus. We assessed all outcomes closest to three months' follow-up (primary point of interest) and maximum follow-up. Main results We included three trials: two trials randomising 61 participants to induced hypertension versus no intervention, and one trial randomising 224 participants to lowered blood pressure versus placebo. All trials were at high risk of bias. The certainty of the evidence was very low for all outcomes. Induced hypertension versus control Two trials randomised participants to induced hypertension versus no intervention. Meta-analysis showed no evidence of a difference between induced hypertension versus no intervention on death from all causes (risk ratio (RR) 1.60, 95% confidence interval (CI) 0.57 to 4.42; P = 0.38; I2 = 0%; 2 trials, 61 participants; very low-certainty evidence). Trial sequential analyses showed that we had insufficient information to confirm or reject our predefined relative risk reduction of 20% or more. Meta-analysis showed no evidence of a difference between induced hypertension versus no intervention on death or dependency (RR 1.29, 95% CI 0.78 to 2.13; P = 0.33; I2 = 0%; 2 trials, 61 participants; very low-certainty evidence). Trial sequential analyses showed that we had insufficient information to confirm or reject our predefined relative risk reduction of 20% or more. Meta-analysis showed no evidence of a difference between induced hypertension and control on serious adverse events (RR 2.24, 95% CI 1.01 to 4.99; P = 0.05; I2 = 0%; 2 trials, 61 participants; very low-certainty evidence). Trial sequential analysis showed that we had insufficient information to confirm or reject our predefined relative risk reduction of 20% or more. One trial (41 participants) reported quality of life using the Stroke Specific Quality of Life Scale. The induced hypertension group had a median of 47 points (interquartile range 35 to 55) and the no-intervention group had a median of 49 points (interquartile range 35 to 55). The certainty of evidence was very low. One trial (41 participants) reported rebleeding. Fisher's exact test (P = 1.0) showed no evidence of a difference between induced hypertension and no intervention on rebleeding. The certainty of evidence was very low. Trial sequential analysis showed that we had insufficient information to confirm or reject our predefined relative risk reduction of 20% or more. One trial (20 participants) reported delayed cerebral ischaemia. Fisher's exact test (P = 1.0) showed no evidence of a difference between induced hypertension and no intervention on delayed cerebral ischaemia. The certainty of the evidence was very low. Trial sequential analysis showed that we had insufficient information to confirm or reject our predefined relative risk reduction of 20% or more. None of the trials randomising participants to induced hypertension versus no intervention reported on hydrocephalus. No subgroup analyses could be conducted for trials randomising participants to induced hypertension versus no intervention. Lowered blood pressure versus control One trial randomised 224 participants to lowered blood pressure versus placebo. The trial only reported on death from all causes. Fisher's exact test (P = 0.058) showed no evidence of a difference between lowered blood pressure versus placebo on death from all causes. The certainty of evidence was very low. Authors' conclusions Based on the current evidence, there is a lack of information needed to confirm or reject minimally important intervention effects on patient-important outcomes for both induced hypertension and lowered blood pressure. There is an urgent need for trials assessing the effects of altering blood pressure in people with acute subarachnoid haemorrhage. Such trials should use the SPIRIT statement for their design and the CONSORT statement for their reporting. Moreover, such trials should use methods allowing for blinded altering of blood pressure and report on patient-important outcomes such as mortality, rebleeding, delayed cerebral ischaemia, quality of life, hydrocephalus, and serious adverse events." @default.
• W2885472080 created "2018-08-22" @default.
• W2885472080 creator A5019275846 @default.
• W2885472080 creator A5020343529 @default.
• W2885472080 creator A5024824441 @default.
• W2885472080 creator A5059880098 @default.
• W2885472080 creator A5077175077 @default.
• W2885472080 date "2018-08-14" @default.
• W2885472080 modified "2023-09-23" @default.
• W2885472080 title "Interventions for altering blood pressure in people with acute subarachnoid haemorrhage" @default.
• W2885472080 cites W1574906247 @default.
• W2885472080 cites W1601774535 @default.
• W2885472080 cites W1966109927 @default.
• W2885472080 cites W1971441597 @default.
• W2885472080 cites W1982345917 @default.
• W2885472080 cites W1994372300 @default.
• W2885472080 cites W2000898146 @default.
• W2885472080 cites W2005732901 @default.
• W2885472080 cites W2007919258 @default.
• W2885472080 cites W2012000361 @default.
• W2885472080 cites W2027974297 @default.
• W2885472080 cites W2029372700 @default.
• W2885472080 cites W2039418122 @default.
• W2885472080 cites W2039758143 @default.
• W2885472080 cites W2040203186 @default.
• W2885472080 cites W2044287170 @default.
• W2885472080 cites W2049852456 @default.
• W2885472080 cites W2059586623 @default.
• W2885472080 cites W2060552257 @default.
• W2885472080 cites W2065201126 @default.
• W2885472080 cites W2086148792 @default.
• W2885472080 cites W2093011739 @default.
• W2885472080 cites W2093790057 @default.
• W2885472080 cites W2094500440 @default.
• W2885472080 cites W2095268948 @default.
• W2885472080 cites W2104634108 @default.
• W2885472080 cites W2105079312 @default.
• W2885472080 cites W2107328434 @default.
• W2885472080 cites W2108012929 @default.
• W2885472080 cites W2110970000 @default.
• W2885472080 cites W2111062482 @default.
• W2885472080 cites W2114214167 @default.
• W2885472080 cites W2116291080 @default.
• W2885472080 cites W2125445260 @default.
• W2885472080 cites W2128973824 @default.
• W2885472080 cites W2129466357 @default.
• W2885472080 cites W2136265514 @default.
• W2885472080 cites W2136440984 @default.
• W2885472080 cites W2137299577 @default.
• W2885472080 cites W2138188443 @default.
• W2885472080 cites W2138440666 @default.
• W2885472080 cites W2142917088 @default.
• W2885472080 cites W2143959795 @default.
• W2885472080 cites W2144338223 @default.
• W2885472080 cites W2147069143 @default.
• W2885472080 cites W2150112944 @default.
• W2885472080 cites W2156098321 @default.
• W2885472080 cites W2157006832 @default.
• W2885472080 cites W2157508850 @default.
• W2885472080 cites W2157823046 @default.
• W2885472080 cites W2159799981 @default.
• W2885472080 cites W2160858624 @default.
• W2885472080 cites W2165010366 @default.
• W2885472080 cites W2283298897 @default.
• W2885472080 cites W2317764477 @default.
• W2885472080 cites W2320749482 @default.
• W2885472080 cites W2326096858 @default.
• W2885472080 cites W2345517591 @default.
• W2885472080 cites W2409181187 @default.
• W2885472080 cites W2499089014 @default.
• W2885472080 cites W2510973590 @default.
• W2885472080 cites W2561826548 @default.
• W2885472080 cites W2768379205 @default.
• W2885472080 cites W2913112014 @default.
• W2885472080 cites W2991792334 @default.
• W2885472080 cites W4211004345 @default.
• W2885472080 cites W4293240757 @default.
• W2885472080 doi "https://doi.org/10.1002/14651858.cd013096" @default.
• W2885472080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8596376" @default.
• W2885472080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34787310" @default.
• W2885472080 hasPublicationYear "2018" @default.
• W2885472080 type Work @default.
• W2885472080 sameAs 2885472080 @default.
• W2885472080 citedByCount "1" @default.
• W2885472080 countsByYear W28854720802021 @default.
• W2885472080 crossrefType "journal-article" @default.
• W2885472080 hasAuthorship W2885472080A5019275846 @default.
• W2885472080 hasAuthorship W2885472080A5020343529 @default.
• W2885472080 hasAuthorship W2885472080A5024824441 @default.
• W2885472080 hasAuthorship W2885472080A5059880098 @default.
• W2885472080 hasAuthorship W2885472080A5077175077 @default.
• W2885472080 hasBestOaLocation W28854720802 @default.
• W2885472080 hasConcept C126322002 @default.
• W2885472080 hasConcept C141071460 @default.
• W2885472080 hasConcept C15744967 @default.
• W2885472080 hasConcept C159110408 @default.
• W2885472080 hasConcept C177713679 @default.
• W2885472080 hasConcept C27415008 @default.
• W2885472080 hasConcept C2776098176 @default.
• W2885472080 hasConcept C2992083352 @default.

• next